<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526420</url>
  </required_header>
  <id_info>
    <org_study_id>15VR7</org_study_id>
    <nct_id>NCT02526420</nct_id>
  </id_info>
  <brief_title>Versartis International Trial in Adults With Long-Acting Growth Hormone</brief_title>
  <acronym>VITAL</acronym>
  <official_title>An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versartis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Versartis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for
      five months in adults with GHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2, dose finding safety study to evaluate an individualized monthly VRS-317 dosing
      regimen in adults with GHD. This is an open-label, international, multicenter study with
      VRS-317 treatment for five months. This treatment period will include monthly dose titrations
      until a subject's mean IGF-I SDS value is within a target range for two consecutive months.
      Subjects will be stratified into three cohorts based on sensitivity to rhGH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the number of subjects with adverse events, concomitant medications, safety labs, vital signs and physical exams</measure>
    <time_frame>5 months</time_frame>
    <description>Safety observations include adverse events, concomitant medications, safety labs, vital signs and physical exams.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Starting doses (proportion of subjects who achieve normalization of IGF-I SDS response during the first dosing interval )</measure>
    <time_frame>5 months</time_frame>
    <description>To evaluate the starting doses of VRS-317 for each cohort as measured by the proportion of subjects who achieve normalization of IGF-I SDS response during the first dosing interval (one month after the first dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose titration plan (proportion of subjects who achieve a mean IGF-I SDS within the defined target range after each dose titration)</measure>
    <time_frame>5 months</time_frame>
    <description>To evaluate the dose titration plan of VRS-317 for each cohort as measured by the proportion of subjects who achieve a mean IGF-I SDS within the defined target range after each dose titration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of VRS-317 by measurement of serum anti-drug antibody (ADA) titers</measure>
    <time_frame>5 months</time_frame>
    <description>To evaluate the immunogenicity of VRS-317 by measurement of serum anti-drug antibody (ADA) titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of VRS-317 by detection of neutralizing antibodies (NAbs)</measure>
    <time_frame>5 months</time_frame>
    <description>To evaluate the immunogenicity of VRS-317 by detection of neutralizing antibodies (NAb)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Cohort A: Somavaratan in Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects &gt;= 35 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Somavaratan in Younger Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects &lt; 35 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Somavaratan in Women on Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somavaratan</intervention_name>
    <description>Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly</description>
    <arm_group_label>Cohort A: Somavaratan in Older Adults</arm_group_label>
    <arm_group_label>Cohort B: Somavaratan in Younger Adults</arm_group_label>
    <arm_group_label>Cohort C: Somavaratan in Women on Estrogen</arm_group_label>
    <other_name>VRS-317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of childbearing potential must have negative pregnancy test and use
             appropriate contraceptive methods

          -  Subjects must have documented GHD during adulthood.

          -  Subjects taking other hormone replacement therapy must have been on a stable course of
             treatment for at least 3 months.

          -  Subjects with underlying disorders responsible for the subject's GHD must have been
             clinically stable for at least 6 months.

          -  Subjects receiving daily rhGH injections must washout for 14 days.

          -  Subjects must provide signed informed consent.

          -  Subjects must have a BMI (kg/m2) between 19.0 and 35.0.

        Exclusion Criteria:

          -  Subjects with diabetes mellitus or inadequate glucose control

          -  Subjects with untreated adrenal insufficiency.

          -  Subjects with free thyroxine outside the normal reference range.

          -  Subjects currently taking oral glucocorticoids, except for physiological maintenance
             doses of oral glucocorticoids in subjects with multiple pituitary hormone
             deficiencies.

          -  Subjects with current significant cardiovascular disease, heart insufficiency of NYHA
             class &gt; 2.

          -  Subjects with current significant cerebrovascular, pulmonary, neurological, renal,
             inflammatory, or hepatobiliary disease.

          -  Subjects with current papilledema.

          -  Subjects with a history of persistent or recurring migraines.

          -  Subjects with current edema (â‰¥ CTCAE Grade 2).

          -  Subjects with current drug or alcohol abuse.

          -  Subjects with a documented history of HIV, current HBV or HCV infection

          -  Subjects with a prior history of malignancy excluding adequately treated non-melanoma
             skin cancers or in situ carcinoma of the cervix.

          -  Women who are pregnant or breastfeeding.

          -  Subjects with a significant abnormality in Screening laboratory results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Rogoff, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Versartis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR Institute Inc.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Research Institute of Orange County</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Research Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Associates of Dallas</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite-UniversitÃ¤tsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D- 45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>B152gw</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Harvey Research Institute</name>
      <address>
        <city>London</city>
        <state>Ec1m 6bq</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull, East Yorkshire</city>
        <state>Hu3 2rw</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>M20 4bx</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.versartis.com</url>
    <description>Company Website</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VRS-317</keyword>
  <keyword>Long Acting Growth Hormone</keyword>
  <keyword>Versartis</keyword>
  <keyword>somavaratan</keyword>
  <keyword>Growth Hormone Deficiency</keyword>
  <keyword>Adult Growth Hormone Deficiency</keyword>
  <keyword>AGHD</keyword>
  <keyword>Growth Hormone Replacement</keyword>
  <keyword>Growth Hormone Replacement Therapy</keyword>
  <keyword>XTEN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

